Uma Borate
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Uma Borate sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Uma Borate: 7 sponsored US clinical trials, 3 recruiting.
Uma Borate sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Secondary Myelodysplastic Syndrome, with 1 trials.
Upper-quartile sponsor footprint
Uma Borate sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
NCT06523556
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
NCT06222580
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
NCT05641831
Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
NCT05379166
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
NCT06930352
TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia
NCT04518345
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
NCT03900949
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Uma Borate pipeline
3 recruiting of 7 indexed (43% open); 2 completed (29%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Secondary Myelodysplastic Syndrome (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Uma Borate: open-pipeline peers nationwide
Peers matched on 7 registered trials and 43% open enrollment, not the therapeutic-area sidebar.
Uma Borate sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 43% open enrollment (± trial volume)
- Alphatec Spine · 43% recruiting · 7 trials
- Clarity Pharmaceuticals · 43% recruiting · 7 trials
- Colorado Center for Reproductive Medicine · 43% recruiting · 7 trials
- David Moss · 43% recruiting · 7 trials
Related
What to do with this Uma Borate page
7 registered trials is a research-attention snapshot, not an endorsement of Uma Borate or any single study.
- 3 of Uma Borate's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Secondary Myelodysplastic Syndrome is the condition Uma Borate studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Secondary Myelodysplastic Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Uma Borate pipeline card: 7 registered trials from official public datasets.Report a data error.